
- Laser (blue, green, red)
- One side-scatter channel
- Two fluorescence channels
- up to 12,000 particles/min
- Lower detection limit 7 nm (gold nanoparticles) to 40 nm (exosomes, viruses)
- High detection limit (1 micron)













EXTRACELLULAR VESICLES

THE ORIGIN AND PHENOTYPING OF EXTRACELLULAR VESICLES

VIRUSES / VACCINES

TRULY QUANTITATIVE MEASUREMENT OF TOTAL TITER AND SUBGROUP TITER OF VIRUS

NANOMEDICINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

MRNA

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

BACTERIA

TRULY QUANTITATIVE MEASUREMENT OF TOTAL BACTERIAL TITRE

NANOMATERIALS

COMPREHENSIVE MEASUREMENT SUITE FOR NANOPARTICLES


VIRUSES / VACCINES

TRULY QUANTITATIVE MEASUREMENT OF TOTAL TITER AND SUBGROUP TITER OF VIRUS






EXTRACELLULAR VESICLES

THE ORIGIN AND PHENOTYPING OF EXTRACELLULAR VESICLES

VIRUSES / VACCINES

TRULY QUANTITATIVE MEASUREMENT OF TOTAL TITER AND SUBGROUP TITER OF VIRUS

NANOMEDICINE

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

MRNA

COMPREHENSIVE MEASUREMENT SUITE FOR NANOSIZED DRUG PRODUCTS

BACTERIA

TRULY QUANTITATIVE MEASUREMENT OF TOTAL BACTERIAL TITRE

NANOMATERIALS

COMPREHENSIVE MEASUREMENT SUITE FOR NANOPARTICLES


High Performance


No Swarm Detection


Label Free


Flexible
Particle Concentration

Measure the absolute concentration of both total particles and subpopulations

Phenotyping

Based on single -molecule fluorescence detection, Phenotype quantify direct from marker labeling intensity.



Size Distribution


Particle Concentration


Multiparameter


Phenotyping
For many years scientists yearned for the possibility of performing flow cytometry to analyse small bio-nanoparticles that are too small to be measured by conventional and high sensitivity instruments. These entities, extracellular vesicles, gene therapy vectors, viruses and drug delivery particles, are promised to become the next generation of therapeutics, but they have been hard to handle and characterise due to their small size and biological or chemical heterogeneity. There is therefore a strong case for bringing flow cytometry capability to the sub-200nm scale.

NanoFCM has developed the NanoAnalyzer platform that now enables true flow-cytometry measurement at the sub-micron scale, and down to particle sizes unreachable by any other flow cytometers (10-40nm depending on the nature of the substrate). Nano-flow cytometry, the technology that underpins the NanoAnalyzer, removes bias and uncertainty stemming from the use of fluorescence signal triggering by using its highly sensitive side-scatter channel to trigger particle events. The single-particle nature of the measurement prevents uncontrolled swarming events, reinforcing data integrity. High resolution of both scatter and fluorescence channels allows the assessment of subpopulations, based on size or on bio-chemical properties.

Nano-flow cytometry’s ability to measure simultaneously a (bio)-nanoparticle population for size, size distribution and bio-chemical properties on a single instrument dramatically improves data quality and throughput compared to the traditional, multiple-techniques approach involving particle characterisation and counting (DLS, NTA, RPS), combined with chemical and biological function assessment (ELISA, Western Blot, Flow Cytometry, PCR). Quantitative measurement of the active and contaminant particles in a single preparation opens up the possibility of characterisation-based nanomedicine regulatory approval, and allows the conduct of large-scale clinical studies. From the research laboratory to the quality control department, NanoFCM delivers comprehensive bio-nano analysis.
